FDA Drug recall D-0520-2016
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-c…
- FDA Drug
- Class III
- terminated
- Published 2015-12-16
On 2015-12-16 the FDA classified a Class III recall of Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-c… by Pfizer, citing failed Dissolution Specification.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0520-2016 |
| Classification | Class III |
| Status | terminated |
| Initiated | 2015-12-02 |
| Published | 2015-12-16 |
| Last updated | 2026-09-13 11:51 UTC |
| Company | Pfizer |
| Distribution | US |
Product
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.
Reason
Failed Dissolution Specification
Identifiers
| ndc | 0025-2752-31 |
|---|---|
| ndc | 0025-2762-31 |
| ndc | 0025-2732-31 |
| ndc | 0025-2742-31 |
| ndc | 0025-2742-51 |
| code_info | Lot #: C150065; C150064, Exp 6/16 |
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:51 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0520-2016%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.